NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
Clinical Trials
13 trialsNCT05152472 2026-01-08
ATEZOGIST
Centre Leon Berard
Phase 2 Recruiting
NCT05282108 2025-03-26
CARCML
Hikma Pharmaceuticals LLC
Recruiting
NCT05467189 2022-07-20
Antineoplastic Drugs in Elderly Patients
Shandong University
Recruiting
NCT02461849 2022-06-15
Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
Samsung Medical Center
Phase 2 Unknown
NCT03381053 2017-12-21
Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation
Shanghai Zhongshan Hospital
Unknown
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT00441155 2013-05-13
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
Novartis
Phase 1 Completed
NCT00611689 2013-02-04
Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00026169 2013-01-10
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
National Cancer Institute (NCI)
Phase 1 Completed
NCT00250042 2011-09-20
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT01271166 2011-01-06
GlivecĀ® Plus m-FOLFOX AvastinĀ® in Advanced Colorectal Cancer
Novartis
Phase 1 Terminated
NCT00180830 2006-09-11
Glivec Phase II Pediatric Study
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated